Objectives: High dose of intravenous sulfamethoxazole and trimethoprim (co-trimoxazole) is often used in immunocompromised patients for the treatment of pneumonia. Current manufacturer's dilution recommendation for intravenous co-trimoxazole (1:25 v/v) requires the administration of 2 L of additional fluid per day causing serious complications including pulmonary oedema. Intravenous administration of concentrated solution of co-trimoxazole may minimise the risk of fluid overload associated side effects. Therefore, the objective of the study was to investigate the physicochemical stability of concentrated intravenous co-trimoxazole solutions.
Methods: Four ampoules of intravenous co-trimoxazole were injected into an infusion bag containing either 480 (1:25 v/v), 380 (1:20 v/v), 280 (1:15 v/v) or 180 (1:10 v/v) mL of glucose 5% solution. Three bags for each dilution (total 12 bags) were prepared and stored at room temperature. An aliquot was withdrawn immediately (at 0 hour) and after 0.5, 1, 2 and 4 hours of storage for high-performance liquid-chromatography (HPLC) analysis, and additional samples were withdrawn every half an hour for microscopic examination. Each sample was analysed for the concentration of trimethoprim and sulfamethoxazole using a stability indicating HPLC method. Samples were assessed for pH, change in colour (visually) and for particle content (microscopically) immediately after preparation and on each time of analysis.
Results: Intravenous co-trimoxazole at 1:25, 1:20, 1:15 and 1:10 v/v retained more than 98% of the initial concentration of trimethoprim and sulfamethoxazole for 4 hours. There was no major change in pH at time zero and at various time points. Microscopically, no particles were detected for at least 4 hours and 2 hours when intravenous co-trimoxazole was diluted at 1:25 or 1:20 and 1:15 v/v, respectively. More than 1200 particles/mL were detected after 2.5 hours of storage when intravenous co-trimoxazole was diluted at 1:15 v/v.
Conclusions: Intravenous co-trimoxazole is stable over a period of 4 hours when diluted with 380 mL of glucose 5% solution (1:20 v/v) and for 2 hours when diluted with 280 mL glucose 5% solution (1:15 v/v).
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319416 | PMC |
http://dx.doi.org/10.1136/ejhpharm-2017-001225 | DOI Listing |
Res Rep Urol
December 2024
Urology Department, Tauranga Hospital, Tauranga, New Zealand.
A 44-year-old healthy Caucasian gentleman presented with fevers and right lower quadrant pain. He had mildly elevated inflammatory markers and computed tomography demonstrated cystic enlargement of the right seminal vesicle concerning for seminal vesicle abscess (SVA). SVA is a rare diagnosis and generally requires drainage for adequate source control.
View Article and Find Full Text PDFActa Trop
January 2025
Department of Medicine, Cairns Hospital, Cairns, Queensland Australia; Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia. Electronic address:
Endocarditis is a very rare complication of Burkholderia pseudomallei infection and prosthetic valve endocarditis rarer still. We present, to our knowledge, the first confirmed Australian case of prosthetic valve endocarditis in a patient with melioidosis. Blood cultures were persistently positive for B.
View Article and Find Full Text PDFAntimicrob Agents Chemother
December 2024
Leiden University Center for Infectious Diseases (LU-CID), Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands.
Fluoroquinolones (FQs) are considered the most effective antimicrobial treatment for Gram-negative prosthetic joint infection (GN-PJI). Alternatives are needed due to increasing FQ resistance and side effects. We aimed to compare different targeted antimicrobial strategies for GN-PJI managed by debridement, antibiotics, and implant retention (DAIR) or one-stage revision surgery (1SR) and to review the literature of oral treatment options for GN-PJI.
View Article and Find Full Text PDFJ Antimicrob Chemother
January 2025
Department of Gastroenterology and Hepatology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
Background: The EASL cystic liver disease guideline states that drug penetration at the site of infection (liver cyst) is essential for successful treatment, but pharmacokinetic (PK) data on cyst penetration are limited.
Objectives: This study aims to investigate tissue penetration of four antibiotics in non-infected liver cysts and explores influencing factors.
Methods: We performed a prospective, randomized single-dose PK-study.
BMJ Case Rep
September 2024
Department of Medicine, Division of Infectious Disease, Rutgers New Jersey Medical School, Newark, New Jersey, USA
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!